Michael D. Greicius

Neurology
213 Quarry Rd
Palo Alto, CA 94304

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 131 publications

Longitudinal plasma proteomics separates diagnostic differences from progression-linked changes in Alzheimer's disease.

Longitudinal plasma proteomics separates diagnostic differences from progression-linked changes in Alzheimer's disease.

Journal: medRxiv : the preprint server for health sciences
Published: July 17, 2026

An APOE *4-Informed Genomic Atlas of the X Chromosome in Alzheimer's Disease.

An APOE *4-Informed Genomic Atlas of the X Chromosome in Alzheimer's Disease.

Journal: medRxiv : the preprint server for health sciences
Published: May 18, 2026

Proteomic Signatures of Protected APOE-ε4 Carriers Reveal Causal Pathways Associated with Delayed Alzheimer's Disease Onset.

Proteomic Signatures of Protected APOE-ε4 Carriers Reveal Causal Pathways Associated with Delayed Alzheimer's Disease Onset.

Journal: medRxiv : the preprint server for health sciences
Published: May 07, 2026

Proteomic signatures of protected APOE ε4 carriers reveal causal pathways associated with delayed Alzheimer's disease onset.

Proteomic signatures of protected APOE ε4 carriers reveal causal pathways associated with delayed Alzheimer's disease onset.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: May 04, 2026

Population-scale burden analysis of rare damaging coding variants identifies novel risk genes for Alzheimer's disease and Parkinson's disease.

Population-scale burden analysis of rare damaging coding variants identifies novel risk genes for Alzheimer's disease and Parkinson's disease.

Journal: medRxiv : the preprint server for health sciences
Published: March 23, 2026

Population-scale burden analysis of rare damaging coding variants identifies novel risk genes for Alzheimer's disease and Parkinson's disease.

Population-scale burden analysis of rare damaging coding variants identifies novel risk genes for Alzheimer's disease and Parkinson's disease.

Journal: medRxiv : the preprint server for health sciences
Published: March 23, 2026

APOE*4 risk-modifying genes and drug targets in Alzheimer's disease through cell-type-specific genomic analyses.

APOE*4 risk-modifying genes and drug targets in Alzheimer's disease through cell-type-specific genomic analyses.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: February 05, 2026

Effects of α-synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging.

Effects of α-synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: December 23, 2025

APOE*4 Risk-Modifying Genes and Drug Targets in Alzheimer's Disease through Cell-Type Specific Genomic Analyses.

APOE*4 Risk-Modifying Genes and Drug Targets in Alzheimer's Disease through Cell-Type Specific Genomic Analyses.

Journal: medRxiv : the preprint server for health sciences
Published: December 17, 2025

Integrative Genetic, Proteogenomic, and Multi-omics Analyses Reveal Sex-Biased Causal Genes and Drug Targets in Alzheimer's Disease.

Integrative Genetic, Proteogenomic, and Multi-omics Analyses Reveal Sex-Biased Causal Genes and Drug Targets in Alzheimer's Disease.

Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025

Long-read genome sequencing and multi-omics in aging and neurodegeneration.

Long-read genome sequencing and multi-omics in aging and neurodegeneration.

Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025

ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer's Disease Pathogenesis.

ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer's Disease Pathogenesis.

Journal: Biochemistry
Published: October 24, 2025
Showing 1-12 of 131

Last Updated: 09/26/2026